Back to Authors

Cagiannos, Ilias

https://orcid.org/0000-0002-1066-2986

Mayo Clinic

Ottawa Hospital

Citations 3

Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial
McAlpine, Kristen , Morash, Christopher , Cnossen, Sonya, Mallick, Ranjeeta , Finelli, Antonio , Jewett, Michael A.S. , Leibovich, Bradley C. , Kapoor, Anil , Pouliot, Frédéric , Izawa, Jonathan I., Rendon, Ricardo , Cagiannos, Ilias , Breau, Rodney H. , Fergusson, Dean A , Knoll, Greg A. , Lavallée, Luke T. , Cook, Jonathan Alistair

Journal of Urology | December 21, 2020 | Volume: 205 | Issue: 5 | Pages: 1303-1309

10.1097/ju.0000000000001517 Get It

Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis
Breau, Rodney H. , Karnes, R. Jeffrey , Farmer, Sara A., Thapa, Prabin , Cagiannos, Ilias , Morash, Christopher , Frank, Igor

BJU International | August 12, 2013 | Volume: 113 | Issue: 6 | Pages: 900-906

10.1111/bju.12403 Get It

Objective To evaluate survival in patients after radical cystectomy ( RC ) who presented with non‐muscle‐invasive urothelial carcinoma and progressed to muscle invasion during surveillance. Our secondary objective was to evaluate the association between clinical factors before RC and survival. Patients and Methods In all, 981 consecutive M ayo C linic RC patients without a history of radiation or systemic chemotherapy were reviewed. Of these, 190 had RC after they progressed from non‐muscle invasive disease to muscle invasion (progressed to ≥ pT2 ). These patients were compared to 310 patients who had RC before muscle invasion (≤ pT1 ), and 481 patients who had muscle invasion at initial presentation (presented with ≥ pT2 ). Survival estimates were generated using the K aplan– M eier method and compared using the log‐rank test, while adjusted analyses were performed using C ox proportional hazard regression models. Results Patients who progressed to muscle invasion on surveillance had a higher risk of death than patients who initially presented with muscle invasion (overall survival hazard ratio [ HR ] 1.3; 95% confidence interval [ CI ] 1.0, 1.5). The estimated 5‐year cancer‐specific survival was 85.4% for patients presenting with ≤ pT1 , 52.9% for patients who progressed to ≥ pT2 , and 62.4% for patients who presented with ≥ pT2 ( P < 0.001). The corresponding 5‐year overall survival rates were 70.0%, 42.1%, and 49.5% ( P < 0.001). Of the patients who initially presented with non‐muscle‐invasive disease, progression to muscle invasion was associated with increased risk of cancer‐specific death (adjusted HR 2.38; 95% CI 1.6, 3.5). Lack of information about patients who presented without muscle invasion and never received RC is the major limitation of this study. Conclusions Despite close surveillance, many patients who progress to muscle invasion will die from bladder cancer. Patients who progress to muscle invasion on surveillance seem to have particularly aggressive disease and may benefit from multimodal treatments.